Here are the latest stories being discussed in biopharma today:

1. Moderna, after experiencing growth last year, is now warning of potential losses. They are planning a strategic way back to profitability. The biotech firm’s focus has shifted from discussing early-stage research to instead putting emphasis on their pipeline’s readouts from ongoing Phase III programmes.

2. C4 Therapeutics has laid off 30% of its staff in a cost-cutting move. They now plan to concentrate their resources on programs with the greatest potential for value creation and patient impact.

3. Coherus Biosciences has decided to exit a TIGIT pact with the Chinese company Junshi, three months after buying out Surface Oncology.

4. Catalent is emphasising their plans to manufacture GLP-1 drugs after their stock rose in price. The firm has set its sights on GLP-1 and gene therapies to increase its revenue for this year.

5. Company Aclaris shared mixed results for its JAK inhibitor during a Phase IIb eczema study. They are now seeking a partner to continue the next steps of the study.

6. Myrobalan Therapeutics, a central nervous system biotech company, has raised $24 million in its round of Series A fundraising. The funds will be used to bring their four CNS therapeutic candidates into clinics which aim to either repair or restore functions in neurodegenerative patients.

7. The eye care specialist Alcon has announced a Phase III win for their dry eye drug and plans to file for FDA approval in mid-2024.

8. The new CEO of Walgreens, has explained the pharmacy chain’s strategy for survival as a standalone business.

9. Additionally, the CEO believes it would be easy to run their UK operation, Boots, separately amid talks of splitting.

10. The firms LinkedUp and TianTi have ended their legal dispute with Adimab over a yeast-based antibody platform.